Global Ventricular Assist Devices Market to reach $1.2 Billion by 2014, According to New Report by Global Industry Analysts, Inc.

Global Ventricular Assist Devices Market to reach $1.2 Billion by 2014, According to New Report by Global Industry Analysts, Inc.

Driven by enhanced focus on development of next generation devices, and widening demand and supply gap for heart transplantation, the global market for ventricular assist devices is projected to exceed $1.2 billion by 2014.

San Jose, CA (PRWEB) February 19, 2009 -- Globally, about one million people suffer from end-stage heart failure. With demand for heart transplantation, the traditional procedure for end-stage heart failure, surpassing the availability of donor hearts, use of ventricular assist devices (VADs) has emerged as an ideal alternative form of treatment for such patients. Development of VADs with improved design, features and durability is expected to expand its adoption across a broader patient population, including women and children.

Besides, the arrival of second generation and third generation VADs has expanded the scope of using destination therapy as an early intervention measure in the treatment of heart failure, thereby offering hope to several heart failure patients. Destination Therapy holds vast potential in the overall ventricular assist devices (VAD) (http://www.strategyr.com/Ventricular_Assist_Devices_Market_Report.asp) market, driven primarily by the benefits of procedure when compared to conventional heart transplantations. Further, the procedure holds promise owing to its use among patients who are otherwise ineligible for donor hearts due to old age or severe sickness.

United States represents the largest market for VADs, as stated in a recent report by Global Industry Analysts, Inc. A major driver for the use of VADs in United States is the recommendation by various medical associations for using alternative therapies (including VADs) in the treatment of advanced stage cardiac failure patients. The adoption of VADs is also affected by factors such as cost of device, competition from drug industry, reimbursement levels, and time period for gaining FDA approvals.

Thoratec Corporation is the predominant player with about 50% share of the global VAD market. Other key players operating in the market include Abiomed Inc., Berlin Heart GmbH, EvaHeart Medical USA Inc., Jarvik Heart Inc., MicroMed Cardiovascular Inc., SynCardia Systems Inc., Terumo Heart Inc., Ventracor Limited, and World Heart Corporation.

The report titled "Ventricular Assist Devices: A Global Strategic Business Report" published by Global Industry Analysts, Inc., provides a review of market dynamics, trends, issues, and competition pertaining to the market. The report enumerates recent product introductions/innovations, developments, mergers, acquisitions and other strategic industry activities. Analysis is presented for the period 2005-2015 for United States, Europe, and Rest of World.

For more details about this research report, please visit

http://www.strategyr.com/Ventricular_Assist_Devices_Market_Report.asp

About Global Industry Analysts, Inc.

Global Industry Analysts, Inc., (GIA) (http://www.strategyr.com) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world's largest market research publishers. The company employs more than 700 people worldwide and publishes more than 880 full-scale research reports each year. Additionally, the company also offers a range of more than 60,000 smaller research products including company reports, market trend reports and industry reports encompassing all major industries worldwide.

Global Industry Analysts, Inc.

Telephone 408-528-9966

Fax 408-528-9977

Web Site http://www.StrategyR.com

###

Contact Information Public Relations

Global Industry Analysts, Inc.

http://www.StrategyR.com/

(408) 528-9966

Landmark Trial Provides Vital Information for Cardiac Disease Treatment

Landmark Trial Provides Vital Information for Cardiac Disease Treatment

NorthShore University HealthSystem Ted Feldman, M.D., Lead Investigator

Evanston, IL. -- NorthShore University HealthSystem (http://www.northshore.org/) (NorthShore) has played a leading role in a landmark clinical trial comparing two forms of treatment for patients with severe coronary artery disease (CAD). The results were published on-line in this week's issue of the New England Journal of Medicine.

The SYNTAX trial was a clinical research study that compared percutaneous coronary intervention (PCI) with drug-eluting stents and coronary artery bypass surgery (CABG) in patients with three-vessel and left main coronary disease. The trial results did not show any statistically significant differences between PCI and CABG in rates of death or heart attack, an excess of stroke in the CABG treated patients, and a greater need for repeat PCI procedures in the stent treated patients. These are better outcomes for PCI than have been seen in prior trials in less complex patients.

"At NorthShore, we experienced stunning outcomes in patients whose only option would have previously been bypass surgery," said Ted Feldman, M.D, F.S.C.A.I., Director of Cardiac Catheterization Laboratory, NorthShore University HealthSystem, and a lead investigator of the trial. "The data in this study will provide cardiologists with additional information as they determine treatment therapy for patients with complex CAD."

The trial is the first randomized, controlled clinical trial to compare these two treatments in patients with left main disease and/or three-vessel disease, who are typically treated with CABG and represent a population with far more complex anatomy and advanced disease than those studied in prior drug-eluting stent (DES) clinical trials.

There were 1,800 patients enrolled in the randomized arm of the trial. All patients were assessed by a multidisciplinary team including an interventional cardiologist and a cardiac surgeon. If both the cardiologist and surgeon felt that they could offer equivalent complete revascularization, patients were randomized 1:1 into one of the two treatment strategies. If either the cardiologist or surgeon felt that one or the other revascularization technique was the preferred option, due to technical considerations or co-morbidity, for example, then patients were recruited into one of two parallel, nested registries for PCI or CABG. Thus, patients in the PCI registry had been rejected for cardiac surgery.

About NorthShore University HealthSystem

Headquartered in Evanston, Ill., NorthShore University HealthSystem (NorthShore) is a comprehensive, fully integrated, healthcare delivery system that serves the greater North Shore and northern Illinois communities. The system includes three Hospitals--Evanston Hospital, Glenbrook Hospital and Highland Park Hospital--and a fourth, Skokie-based Rush North Shore Hospital, to be added in January 2009. In addition, the healthsystem has more than 2,000 affiliated physicians, including a 550-physician, multispecialty physician group practice with over 70 office locations-- NorthShore University HealthSystem Medical Group. Further, NorthShore is committed to excellence in its academic mission and supports teaching and research as the principal teaching affiliate of the University of Chicago's Pritzker School of Medicine. The NorthShore University HealthSystem Research Institute, with more than $100 million of grants, focuses on clinical and translational research, including leadership in outcomes research and clinical trials.

NorthShore has annual revenues of $1.5 billion and a staff of more than 8,000. The healthsystem has significant capabilities in a wide spectrum of clinical programs, including cancer, heart, orthopaedics, high-risk maternity and pediatrics. NorthShore is a national leader in the implementation of innovative technologies, including electronic medical records, (EMR ). In 2003, the healthsystem was among the first in the country to successfully launch a systemwide EMR with demonstrable benefits in quality, safety, efficiency and service to patients. NorthShore has been recognized by multiple national organizations for this notable achievement. Visit http://www.northshore.org/

CONTACT: Amy Ferguson

Senior Director, Public Relations

NorthShore University HealthSystem

(847) 570-3146

###

Contact Information Amy Ferguson

Northshore University HealthSystem

http://www.northshore.org/

847-570-3146